(+/-)15-epi-PGE(2)(k) | 154170-57-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (+/-)15-epi-PGE(2)(k)
• 英文别名: (+/-)PGE(2)；Prostaglandin E-2；(Z)-7-[3-hydroxy-2-[(E)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
• CAS: 154170-57-7
• 化学式: C₂₀H₃₂O₅
• 分子量: 352.471
• InChiKey: XEYBRNLFEZDVAW-ZQDYKODVSA-N

物化性质

• 沸点：
  530.1±50.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 安全说明：
  S53

文献信息

• MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES
  申请人：Partikula LLC

  公开号：US20180028647A1

  公开（公告）日：2018-02-01

  Compositions of a modulator of cell metabolism, typically targeting cellular glycolysis, preferably with a targeting moiety, attached directly or indirectly to the inhibitor, or to a nanoparticle or other delivery vehicle thereof, and methods of use for treating cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases are provided. Pharmaceutical compositions including the targeted modulator and a pharmaceutically acceptable carrier are also provided. The pharmaceutical compositions can be administered to a subject in need thereof in an effective amount to reduce one or symptoms of the cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases alone or prior to or in conjunction with a further therapy such as radiotherapy.

  提供了细胞代谢调节剂的组成，通常以靶向细胞糖酵解为目标，最好带有一个靶向基团，直接或间接连接到抑制剂，或连接到纳米颗粒或其他递送载体上，并提供了用于治疗癌症、增生性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的方法。还提供了包括靶向调节剂和药学上可接受的载体的药物组合物。这些药物组合物可以以有效剂量给需要的受试者使用，以减少癌症、增生性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的症状之一或多个，独立使用或在放疗等进一步治疗之前或同时使用。
• Cationic materials and formulations for drug delivery
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：US10022334B2

  公开（公告）日：2018-07-17

  Cationic polymers are provided for delivering anionic active agents, preferably in the form or nanoparticles and other nanostructures. The polymer can be a polycation homopolymer or a copolymer containing a polycation block. The polycations and polycation containing polymers can contain dicarboxylic acid ester units and units of (a-amino acid)-α, ω-alkylene diester units. The nanoparticles can contain high loadings of anionic active agents, with sustained release of the active agents. Methods of making the polycations and polycation containing polymers are provided. Methods of making the nanoparticles and formulating them for administration to an individual in need thereof are also provided.

  阳离子聚合物可用于递送阴离子活性剂，最好是以纳米颗粒或其他纳米结构的形式。聚合物可以是阳离子均聚物或含有阳离子嵌段的共聚物。多阳离子和含有多阳离子的聚合物可以含有二羧酸酯单元和（a-氨基酸）-α，ω-亚烷基二酯单元。这种纳米颗粒可含有大量阴离子活性剂，并能持续释放活性剂。本文还提供了制造聚阳离子和含聚阳离子聚合物的方法。此外，还提供了纳米颗粒的制造方法，以及将其配制成给需要的人服用的方法。
• Nanoparticle-mediated delivery of cytokines for maintenance of the regulatory T cell phenotype
  申请人：Yale University

  公开号：US10034917B2

  公开（公告）日：2018-07-31

  Compositions for delivery of growth factors needed for stable Tregs and methods of use thereof are provided. In preferred embodiments, the compositions can induce, increase, or enhance a functionally robust induced CD4 Treg population (e.g., Foxp3+ Treg) in vivo or ex vivo. The compositions generally include delivery vehicles including TGF-β and IL-2. Delivery vehicles include, for example, polymeric particles, silica particles, liposomes, or multilamellar vesicles. The TGF-β and IL-2 are typically co-loaded into, attached to the surface of, and/or enclosed within the delivery vehicle into the same particle for simultaneous co-delivery to cells such as T cells. Preferably the delivery vehicles are targeted to CD4. The compositions and cells treated therewith can be used in various methods of treating, for example, inflammation, inflammatory and autoimmune diseases and disorders, and inducing or maintaining tolerance including graft and transplant tolerance.

  本研究提供了输送稳定 Tregs 所需的生长因子的组合物及其使用方法。在优选的实施方案中，这些组合物可以在体内或体外诱导、增加或增强功能稳健的诱导型 CD4 Treg 群体（如 Foxp3+ Treg）。组合物一般包括 TGF-β 和 IL-2 的递送载体。递送载体包括聚合物颗粒、二氧化硅颗粒、脂质体或多胶束囊泡等。TGF-β和IL-2通常被共同载入、附着在输送载体的表面和/或封闭在同一颗粒内，以便同时共同输送给细胞，如T细胞。输送载体最好以 CD4 为靶标。组合物和经其处理的细胞可用于各种治疗方法，例如炎症、炎症和自身免疫性疾病和紊乱，以及诱导或维持耐受性，包括移植物和移植耐受性。
• Modifications of therapeutic agents for enhanced delivery to target sites
  申请人：Partikula LLC

  公开号：US10478492B2

  公开（公告）日：2019-11-19

  Compositions of a modulator of cell metabolism, typically targeting cellular glycolysis, preferably with a targeting moiety, attached directly or indirectly to the inhibitor, or to a nanoparticle or other delivery vehicle thereof, and methods of use for treating cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases are provided. Pharmaceutical compositions including the targeted modulator and a pharmaceutically acceptable carrier are also provided. The pharmaceutical compositions can be administered to a subject in need thereof in an effective amount to reduce one or symptoms of the cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases alone or prior to or in conjunction with a further therapy such as radiotherapy.

  本研究提供了细胞代谢调节剂的组合物，通常以细胞糖酵解为靶标，优选带有靶向分子，直接或间接连接到抑制剂上，或连接到其纳米颗粒或其他递送载体上，以及用于治疗癌症、增殖性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的方法。还提供了包括靶向调节剂和药学上可接受的载体的药物组合物。这些药物组合物可以以有效量施用给有需要的受试者，以减少癌症、增殖性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的一种或多种症状，可以单独施用，也可以在放疗等进一步治疗之前或与放疗一起施用。
• NANOPARTICLE-MEDIATED DELIVERY OF CYTOKINES FOR MAINTENANCE OF THE REGULATORY T CELL PHENOTYPE
  申请人：Yale University

  公开号：US20160361265A1

  公开（公告）日：2016-12-15

  Compositions for delivery of growth factors needed for stable Tregs and methods of use thereof are provided. In preferred embodiments, the compositions can induce, increase, or enhance a functionally robust induced CD4 Treg population (e.g., Foxp3+ Treg) in vivo or ex vivo. The compositions generally include delivery vehicles including TGF-β and IL-2. Delivery vehicles include, for example, polymeric particles, silica particles, liposomes, or multilamellar vesicles. The TGF-β and IL-2 are typically co-loaded into, attached to the surface of, and/or enclosed within the delivery vehicle into the same particle for simultaneous co-delivery to cells such as T cells. Preferably the delivery vehicles are targeted to CD4. The compositions and cells treated therewith can be used in various methods of treating, for example, inflammation, inflammatory and autoimmune diseases and disorders, and inducing or maintaining tolerance including graft and transplant tolerance.